当前位置：   首页 > 需求大厅

 >  生产研发 

雷贝拉唑钠小试工艺和少量合格样品，原料药合成的   [更多]

硝酸胍路线或者丙二腈路线，要求成本控制在10万左右，能提供详细资料 中文别名： ;嘧啶胺; 英文名称： 2-Amino-4,6-dimethoxypyrimidine 英文别名： ;4,6-Dimethoxypyrimidin-2-amine; EINECS号： 252-969-6 分子式： C6H9N3O2 分子量： 155.1546 InChI： InChI=1/C6H9N3O2/c1-10-4-3-5(11-2)9-6(7)8-4/h3H,1-2H3,(H2,7,8,9) 密度： 1.229g/cm3 熔点： 94-96℃ 沸点： 356.4°C at 760 mmHg 闪点： 169.4°C 物化性质： 熔点 94-96°C   [更多]

要求：能有效提高在黄姜内提取皂素收率，提高黄姜资源的利用率，降低企业的生产成本。   [更多]

 我公司三期项目2.5万吨/年乙叉降冰片烯项目，需要对多个精馏塔进行连续串级控制，亟需配套的ENB在线检测工艺，要求能够做到迅速、精确，设备简便。   [更多]

技术求购碳酰肼或卡巴肼工业化生产成熟技术。   [更多]

主要内容和技术经济指标          稀土磁铁黑片厚度大约在(0.35?0.8mm)之间，采用传统硫酸镍，氨基磺酸镍电镀方式，整套工艺下来，磁通数值损耗在15%以上，亟需通过改善前处理方式或者电镀液配方，在保证盐雾试验信赖性的前提下，减少这一损耗   [更多]

可使生物降解的长效制剂微胶囊技术是一种药物控释技术。在授控的较长的一段时间药物缓慢释放。在过去的二十年中，武田公司已经完善了其专有技术，即具有微胶囊的长效制剂，能在人体的6个多月保持血药浓度。武田希望能有一种技术，即在确定的治疗药物，使用缓释长效制剂微胶囊技术能在任何人体组织上定向使用。具体如下：{https://www.innocentive.com/ar/challenge/9933674} AWARD: varies | DEADLINE: 1/26/15 | ACTIVE SOLVERS: 28 | POSTED: 12/10/14 Depot formulation using a biodegradable microcapsule is one technique for the controlled delivery of pharmaceuticals. The drug is slowly released over an extended period of time in a controlled manner. During the past two decades, Takeda has perfected its proprietary technology, which features a microcapsule depot formulation that maintains drug plasma levels for more than 6 months in humans. Takeda wishes to identify therapeutic agents that will benefit from sustained release through depot formulation using microcapsule technology. This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with a goal of establishing a Takeda funded collaborative partnership. A finder’s fee of $3,000 will be offered at the Seeker’s sole discretion to submission(s) that provide contacts which meet the criteria of the Challenge. Source: InnoCentive Challenge ID: 9933674 Challenge Overview Takeda is well known for its superior depot formulation using microcapsule technology. Controlled sustained release of drugs is achieved using either PLGA (poly-lactic-co-glycolic acid) or PLA (poly-lactic acid) polymer to make microspheres. This core technology is capable of producing injectable formulations that are biodegradable and release drugs over a period of weeks to months. By formulating drugs using this best-in-class approach, Takeda hopes to apply their microcapsule technology to improve the efficacy and safety of known therapeutics compared to the existing administration methods, while providing alternative treatment options to patients with unmet medical needs. In other words, Takeda makes this   [更多]

2-氨基-3,5-二溴苯甲醛成熟工业化生产工艺。   [更多]

现向外界实单求购(S)-4-乙基-4-羟基-7,8-二氢-1H-吡喃O[3,4-F]吲哚嗪-3,6,10(4H)-酮 CAS: 110351-94-5 分子式： C13H13NO5 分子量： 263.24602 有此产品的请与我联系   [更多]

 我公司承接一段重质芳烃溶剂油，来源于C9馏分切割，流程在180～240℃，硫含量在50～80ppm，胶质含量50ppm左右。现寻求方法能将该芳烃油硫含量降低至10ppm以下，且胶质含量小于10ppm。亟待拥有技术或设备的研发机构或企业联系   [更多]